COLO B Coloplast A/S Class B

Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST

Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST

Tuesday, 19 August 2025 at 11.00 - 12.00h CEST

In connection with the publication of Coloplast’s interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.

The webcast of the conference call will be available during and after the event.



Coloplast will be represented by:

Lars Rasmussen - Interim CEO

Anders Lonning-Skovgaard - Executive Vice President, CFO

Aleksandra Dimovska - Vice President, Investor Relations

Kristine Husted Munk - Senior Manager, Investor Relations

Simone Dyrby Helvind - Senior Manager, Investor Relations



Webcast

For participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below:



Dial-in details

To actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details.

 

For more information, please contact:

Aleksandra Dimovska - Vice President, Investor Relations

Tel.: / direct: . E-mail:

Kristine Husted Munk - Senior Manager, Investor Relations

Tel.: / direct: . E-mail:

Simone Dyrby Helvind - Senior Manager, Investor Relations

Tel.: / direct: . E-mail: 

Julie Sommer Müggler - Coordinator & PA, Investor Relations

Tel.: / direct: . E-mail: 

 

Coloplast will be available on individual phone lines after the conference call for further questions.

Attachment



EN
08/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’

Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’ Den nye 5-årige strategi, Impact4, vil blive lanceret i dag på selskabets Capital Markets Day 2025. Strategien Impact4 sætter kunden i centrum og udstikker samtidig et ambitiøst mål for selskabet – at hjælpe 4 millioner mennesker på lang sigt. Med Impact4 fokuserer vi på fire strategiske prioriteter, der er afgørende for vores succes og værdiskabelse: ’Grow through innovative customer offerings’ ved at sætte standarden for sundhedspleje og ved at skabe et stærkt fokus på kunderne på tværs af alle vores forretningsområder.’Unl...

 PRESS RELEASE

Coloplast A/S - Coloplast presents new 5-year strategy, Impact4

Coloplast A/S - Coloplast presents new 5-year strategy, Impact4 The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With Impact4, we focus on four strategic priorities which are essential to our success and value creation: Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity across all our business areas.Unlock next level e...

 PRESS RELEASE

Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye fi...

Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye finansielle forventninger frem mod 2030 I forbindelse med lanceringen af Coloplasts nye 5-årige strategi, Impact4, offentliggør virksomheden en ny finansiel ambition med en organisk omsætningsvækst på 7-8 % (5-årige CAGR) frem til regnskabsåret 2029/30, en vækst i absolut EBIT* på niveau med eller over omsætningsvæksten i perioden og et afkast af investeret kapital (ROIC) på mere end 20 % i regnskabsåret 2029/30. På sin Capital Markets Day den 2. september 2025 vil Coloplast præsentere en ny 5-årig strategi, Impact4. I fo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch